Hair Loss Treatment Type:
Dual 5-alpha reductase inhibitor in an oral softgel
GI197111X is a new dual 5-alpha reductase inhibitor which could be GlaxoSmithKline’s successor to Dutasteride / Avodart. Because Glaxo already has a potent dual 5-alpha reductase inhibitor on the market (Avodart), there is no reason to conduct Phase I or II FDA clinical trials unless they believe it is superior to their existing marketed medicine for some reason.
Last reported in small scale clinical trials (FDA Phase I/II)